ライフサイエンスコーパス: treatment with

1 itor alone did not alter gestational length, treatment with 15-PGDH inhibitor + PGE2 or metabolism-re

2 leven (4%) of the 274 patients had PHD after treatment with (177)Lu-DOTATATE: 8 patients (2.9%) devel

3 In the treatment with 2% and 3% of chitosan in the solid solubl

4 Conversely, treatment with 4-methylumbelliferone, a small-molecule i

5 eek break, followed by a cycle of 3 weeks of treatment with a 1-week break, until disease progression

6 Treatment with a 50-mg once-daily dose of opicapone was

7 Notably, sole treatment with a BDNF mimetic, 7,8-dihydroxyflavone hydr

8 the anti-CSF-1 receptor protected mice after treatment with a blocking antibody directed against PD-1

9 otein, and mycelial growth is impaired after treatment with a chitin-synthase inhibitor.

10 sing senescent cells in INK-ATTAC mice or by treatment with a combination of the senolytic drugs dasa

11 Furthermore, pharmacological treatment with a Drd3 agonist, which increases Drd3(LS)

12 INTERPRETATION: Treatment with a neurokinin 3 receptor antagonist (MLE49

13 somatic mutation associated with ECD enabled treatment with a new-targeted systemic agent.

14 ritic outgrowth and number of synapses after treatment with a PERK activator, tunicamycin.

15 starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor.

16 Sublingual treatment with a recombinant food allergen was safe and

17 -1 blocks nuclear localization of LysRS, but treatment with a reverse transcriptase inhibitor does no

18 After a chemical pre-treatment with a silane derivative, bilirubin oxidase fr

19 Here we demonstrate that treatment with a small-molecule Sigma1 inhibitor prevent

20 Treatment with a specific PI3Kdelta inhibitor Idelalisib

21 Treatment with a Syk inhibitor significantly reduced ren

22 between bacterial taxa in the protist-grazed treatments with a higher proportion of positive correlat

23 ease and conducting clinical trials of these treatments, with a focus on preventing congenital centra

24 ng damage and edema, which were absent after treatment with abatacept.

25 Pre-treatment with ABT-627 failed to decrease renal ER stres

26 ction (MI) of 12365 patients enrolled in the Treatment With Adenosine Diphosphate Receptor Inhibitors

27 serum BUN levels before and after the first treatment with ADVOS.

28 ings demonstrate that combining electrolytic treatment with aerobic biodegradation may be a promising

29 play high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour

30 pitopes in brown algae are unmasked by a pre-treatment with alginate lyases to remove alginates.

31 Treatment with all-trans retinoic acid antagonizes stres

32 tive medications, or relapse while receiving treatment with alternative medications were included in

33 ith refractoriness, ineligibility to receive treatment with alternative medications, or relapse while

34 portacaval anastomosis rats were reversed by treatment with ammonia-lowering therapy.

35 Treatment with an Aha1 inhibitor, KU-177, dramatically r

36 Treatment with an antimalarial medication reduced parasi

37 Combined treatment with an EGFR tyrosine kinase inhibitor and Akt

38 ion phase, patients who had progressed after treatment with an EGFR tyrosine kinase inhibitor receive

39 l lineB double bond in 6 was achieved by the treatment with an isonitrile, which led to the formation

40 Treatment with anakinra did not affect peak Vo2 or VE/Vc

41 We found that treatment with anle138b leads to massive melanoma cell d

42 Treatment with anti-Marco-neutralizing Abs and the class

43 itumor immune responses and are resistant to treatment with anti-PD-1.

44 associated with effective tumor control upon treatment with anti-PD-L1 therapy.

45 Treatment with anti-sclerostin antibody and zoledronic a

46 2 cells impaired epithelial integrity, while treatment with anti-TNF-alpha or anti-IL-4Ralpha monoclo

47 olated from liver biopsy led to the targeted treatment with anti-tumor necrosis factor-alpha, which w

48 th Nlrp12 deficency were reversed equally by treatment with antibodies targeting inflammatory cytokin

49 s with proximal deep-vein thrombosis despite treatment with anticoagulant therapy.

50 sfunction With Multimodality Imaging and Its Treatment with Anticoagulation) were included in this an

51 eneration (AMD) who are being considered for treatment with antioxidants and zinc.

52 Immunosuppression treatment with antithymyocyte globulin, methylprednisolo

53 Despite prompt treatment with appropriate antibiotics, there were varia

54 mTOR-induced cap-dependent translation, pre-treatment with AR antagonists including bicalutamide inc

55 cterized potential predictive biomarkers for treatment with AsiDNA, a novel first-in-class DNA repair

56 ts presented a good clinical response to the treatment, with at least stable disease, and only 1 had

57 Furcation defect treatment with autologous PRF combined with 1% ALN gel r

58 formation was further supported by exogenous treatment with autophagy inducer tamoxifen, which rescue

59 Treatment with basimglurant was overall well-tolerated.

60 n's lymphoma and peripheral T-cell lymphoma, treatment with bendamustine alone only achieves modest i

61 se prion disease were completely restored by treatment with benzyl quinolone carboxylic acid (BQCA) a

62 removal of a terminal beta-GlcNAc moiety by treatment with beta-N-acetylglucosaminidase and selectiv

63 Maintenance treatment with bevacizumab monotherapy was continued unt

64 results from a study comparing initial HIV-1 treatment with bictegravir-a novel INSTI with a high in-

65 Treatment with bone morphogenetic protein or SHH pathway

66 ractory or relapsed myeloma who had received treatment with bortezomib, an immunomodulatory drug, or

67 ere insensitive to AtRALF1, and simultaneous treatment with both AtRALF1 and CML38 proteins restored

68 Treatment with both drugs was required to fully suppress

69 F are found in 50% of melanomas and although treatment with BRAF inhibitors (BRAFi) is effective, res

70 c and TfR gene expression was decreased upon treatment with BRD4 inhibitors and c-MYC small interferi

71 harmacological inhibition of cathepsin K, or treatment with calcineurin inhibitor rescued cells from

72 Treatment with camptothecin which transiently stabilized

73 urvived infection in the absence of or after treatment with candidate medical countermeasures.

74 and (3) T-cell ablation with rituximab after treatment with CD20-coexpressing CART123 (CART123-CD20).

75 reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune c

76 served reduction in (18)F-FMISO uptake after treatment with cediranib may be mistakenly interpreted a

77 Long-term treatment with ceftriaxone attenuates the reinstatement

78 linked by isopeptide bonds, are dispersed by treatment with chemical denaturants or soluble competing

79 preterm birth and low birth weight included treatment with chemotherapy and a diagnosis of breast ca

80 cognitive difficulties up to 6 months after treatment with chemotherapy than do age-matched noncance

81 tients should have access to multiple cancer treatments with close monitoring while receiving regimen

82 Treatment with CN-105 was associated with a durable impr

83 e levels were measured using LC-MS following treatment with colistin (2 mg/L) or doripenem (25 mg/L)

84 Antibiotic treatment with combinations of clindamycin and rifampici

85 dverse reactions were minor and responded to treatment with corticosteroids and antihistamines.

86 Treatment with crenolanib attenuated the skin and heart

87 Treatment with CSF1R inhibitors disrupted this crosstalk

88 g propensity score-matched patients starting treatment with dabigatran or warfarin.

89 of a small number of genes, whereas combined treatment with DAC enhanced the effects of the latter fo

90 Treatment with DCA resulted in normalization of several

91 at baseline and at 1, 2, and 4 months after treatment with DEX implants.

92 upon inflammatory stimulation and subsequent treatment with dexamethasone, a powerful antiphlogistic

93 Combined treatment with DHA and Physcion activates AMP-activated

94 transcriptional regulation of SNCA following treatment with different drugs known to regulate alpha-S

95 -intact SOAT1-/SOAT2-CHO cells prepared by a treatment with digitonin (plasma membrane permeabilized)

96 to up-regulate IFN-beta and TNF-alpha after treatment with DMXAA or the natural STING ligand cyclic

97 3 subjecting to DNA-damaging stimuli such as treatment with doxorubicin, was also significantly inhib

98 Long-term treatment with doxycycline does not reduce fatigue sever

99 tion rates and reduces PHH symptoms, as does treatment with drugs that antagonize TLR4-NF-kappaB sign

100 Treatment with dual PI3K/mTOR inhibitor gedatolisib resu

101 Conclusion Results of treatment with duloxetine for AIMSS were superior to tho

102 In contrast, treatment with dynasore failed to alter the surface memb

103 r growth but render tumor cells sensitive to treatment with EGFR tyrosine kinase inhibitors (TKI).

104 Treatment with either botulinum toxin ("chemodenervation

105 Importantly, treatment with either DAC or DAC+KDM5i induced a dramati

106 First-line treatment with either first-generation antipsychotics (a

107 x human fecal microbial communities, whereas treatment with either glycerol or L. reuteri alone was i

108 Although treatment with either IL-6 or soluble IL-6 receptor (sIL

109 Furthermore, in utero treatment with either lithium chloride, an agonist of ca

110 es with NVAMD that were randomly assigned to treatment with either ranibizumab or bevacizumab.

111 In multivariable Cox regression analysis, treatment with either regimen (hazard ratio [HR], 0.43;

112 and a left ventricular EF of 40% or less to treatment with enalapril 10 mg twice daily or sacubitril

113 F, severe hyperkalemia is more likely during treatment with enalapril than with sacubitril/valsartan.

114 Oral treatment with enrofloxacin suppresses CS and production

115 ssigned with equal likelihood to 12 weeks of treatment with escitalopram (10-20 mg/day), duloxetine (

116 raction was observed with placebo treatment, treatment with estradiol attenuated the effects of ACE a

117 Treatment with ethosuximide significantly blocks seizure

118 cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with

119 offer powerful tools for designing effective treatments with fewer side effects.

120 Treatments with fine sediment in the upper 20 cm of the

121 n-KO pups, the genetic deletion of Slc6a4 or treatment with Fluoxetine, a 5-HT reuptake inhibitor, re

122 eated with FK866 at 24, 12, and 0.5 h before treatment with GaIN/LPS and ConA.

123 Prior to treatment with GAs to promote germination, the seeds wer

124 In a model of endotoxemia in the mouse, treatment with glycerophosphoinositol reduced TNF-alpha

125 Indeed, short-term treatment with growth hormone augmented senescent host l

126 Treatment with GSK2334470 or the CDK2 inhibitor dinacicl

127 T-risk (4Ts score >/=4 points), and received treatment with >/=1 dose of the aforementioned anticoagu

128 Treatment with HA35 normalized these changes and also pr

129 this sensitization was normalized by ex vivo treatment with HA35.

130 cells from ethanol- and pair-fed rats after treatment with HA35.

131 e combination of a propidium monoazide (PMA) treatment with haRPA, the so-called viability haRPA, is

132 After treatment with high-dose methylprednisolone (1 g/day, in

133 f PKM2 activity with TEPP-46 and shikonin or treatment with histone deacetylase inhibitors produced s

134 ondrial swelling, which was exacerbated upon treatment with hydrogen peroxide (H2O2).

135 ls maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inh

136 pain reduction at 2 hours among single-dose treatment with ibuprofen and acetaminophen or with 3 dif

137 ple HPV types, including oncogenic types, by treatment with IFN-gamma, an antiviral cytokine that is

138 rs IRF1 and BATF were induced early on after treatment with IL-27 and were required for the different

139 Finally, treatment with IL233 increased the proportion of ST2-bea

140 ain regions implicated in depression and its treatment with imipramine or ketamine.

141 on induction of skin inflammation by topical treatment with imiquimod cream (Aldara).

142 une cell infiltration in claudin-low tumors, treatment with immune checkpoint inhibitory antibodies a

143 l terminal pathway activity under eculizumab treatment with important implications for anti-C5 therap

144 age efflux to draining lymph nodes following treatment with infliximab.

145 st 1 risk factor for hypoglycemia, 32 weeks' treatment with insulin degludec vs insulin glargine U100

146 ents developing depression in the context of treatment with interferon-alpha, a widely used model to

147 However, the ideal duration of treatment with interferon-free regimens, particularly in

148 Treatment with intravitreal aflibercept injection (2 mg)

149 (8.6) (VIVID) letters from the initiation of treatment with intravitreal aflibercept injection throug

150 n a subgroup of laser control eyes receiving treatment with intravitreal aflibercept injection.

151 We evaluated treatment with ipilimumab in asymptomatic or minimally s

152 Treatment with islet Ag-specific regulatory T cells led

153 Treatment with IVM increases the efficacy of ATP to acti

154 burden or survival distributions compared to treatment with (+)-JQ1.

155 blood of clinical responders after 12 wk of treatment with KD025.

156 D) during a depressive episode and following treatment with ketamine.

157 trollable movements known as dyskinesia upon treatment with L-DOPA.

158 An 8-week duration of treatment with LDV/SOF is highly effective in properly s

159 ; (2) T-cell ablation with alemtuzumab after treatment with lentivirally transduced anti-CD123-4-1BB-

160 Compared with chlorthalidone, treatment with lisinopril is not associated with a meani

161 Treatment with locked nucleic acid anti-miR-29a signific

162 mab did not confer a survival advantage over treatment with lomustine alone in patients with progress

163 omewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer

164 s whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-h

165 ts were randomly assigned (1:1:1) to receive treatment with long-acting pasireotide (60 mg intramuscu

166 However, high concentrations or prolonged treatment with low doses of HU can cause cell lethality.

167 To determine whether treatment with mandibular advancement device, the main a

168 Endovascular treatment with mechanical thrombectomy (MT) is beneficia

169 ctancy greater than 4 weeks who consented to treatment with medication.

170 Assessments also gathered information on treatment with medications and confounding factors, such

171 carcinoma cells to apoptosis in response to treatment with microtubule-disrupting drugs, identifying

172 Transcriptional analysis showed that after treatment with miRYR2-U10, the ratio between wild-type a

173 were 129 patients with psoriasis undergoing treatment with MTX, while 107 patients (57 women and 50

174 These effects were blocked by treatment with Na2S or by overexpression of cystathionin

175 nced NSCLC, 27.7% (33/119) were suitable for treatment with National Comprehensive Cancer Network (NC

176 In vitro, treatment with NE attenuated TGF-beta-induced accumulati

177 1 decreased already after a short (3 hours) treatment with necrostatin-1 during renal ischemia-reper

178 oethite occurred in the zero and low PO4(3-) treatments, with negligible transformation in higher PO4

179 Treatment with netarsudil q.d. produced clinically and s

180 d histological damage are all ameliorated by treatment with NitroSynapsin, a new dual-action compound

181 red responses could be corrected in vitro by treatment with NKH-477, a compound discovered as protect

182 increased risk of virological failure during treatment with NNRTI-containing regimens.

183 inutes of exposure to CLCA1 or after a short treatment with nocodazole, consistent with the hypothesi

184 120min at 5 and 10mgL(-1), respectively, in treatments with O3 as gas and dissolved in water.

185 The cathepsin B knockdown and 24-h treatment with OA resulted in increased CD36 expression

186 with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed.

187 Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with e

188 ssed in normal mouse organs before and after treatment with olaparib (n = 14), a PARP inhibitor, or i

189 We evaluated whether response rates to treatment with omalizumab in patients with CSU are linke

190 cquiring mutations in response to vaccine or treatment with one or a cocktail of monoclonal antibodie

191 Participants received protocolized treatment with open-label venlafaxine, up to 300 mg/day

192 rcinoma tumors were allocated to RFA or sham treatment with or without a STAT3 inhibitor (S3I-201 or

193 nimals were allocated to hepatic RFA or sham treatment with or without STAT3 (signal transducer and a

194 Alginate treatments with or without vanillin were effective in pr

195 Treatment with oral corticosteroids may help to reduce t

196 ent and shorter length of hospital stay than treatment with oral morphine, with similar rates of adve

197 s on doxycycline is non-inferior to standard treatment with oral prednisolone for short-term blister

198 crease in the sensitivity of SHR movement to treatment with oryzalin.

199 e effects of which were overcome by combined treatment with osimertinib and SFK inhibitors.

200 S), and the association of immunosuppressive treatments with outcomes are unclear.

201 Treatment with (-)-P7C3-S243 blocked neurodegeneration i

202 was significantly affected (p < 0.05) after treatment with paclitaxel or nocodazole due to changes i

203 Treatment with PE (10(-5) m) or sodium nitroprusside (10

204 in patients develop anti-PEG antibody during treatment with PEGylated medicines, suggesting that gene

205 ast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:

206 thio phenolate species with a boronic ester, treatment with Ph3 BiF2 or Martin's sulfurane gave the c

207 A single treatment with Phen was sufficient to enhance the minera

208 were randomized to receive 12 weeks of blind treatment with placebo or MABp1, a true human antibody t

209 otic or occlusive lesions were randomized to treatment with plain balloon angioplasty (BA) followed b

210 ividuals with bacterial keratitis to topical treatment with povidone-iodine or antibiotics (neomycin-

211 onSG and 12 RD-SG patients were subjected to treatment with prednisone and/or glucocorticoid-sparing

212 Treatment with primaquine significantly reduced the memb

213 in patients with FH at 3 and 6 months after treatment with probucol, a cholesterol-lowering agent.

214 S were measured in healthy neutrophils after treatment with purified albumin from the study groups.

215 Long-term treatment with Py-Im polyamide demonstrated a global dec

216 notypes have been observed following chronic treatment with R-baclofen, a selective agonist of GABAB

217 Treatment with rAAV.Tbeta4 enhanced capillary density an

218 mice, which could be suppressed by combined treatment with rapamycin and an extracellular signal-reg

219 ompared to patients submitted to orthodontic treatment with rapid maxillary expansion and facemask th

220 25 (96%; 95% CI, 80-100) receiving the same treatment with RBV.

221 In this study, we demonstrate that treatment with recombinant human IL-37 reverses the decr

222 Treatment with recombinant S100A9 proteins increased AML

223 is inhibitory effect was fully reversible by treatment with reducing agents.

224 ot have a sustained virologic response after treatment with regimens containing direct-acting antivir

225 Treatment with replacement factor can lead to the develo

226 Treatment with RG-101, an N-acetylgalactosamine-conjugat

227 Combining D2 receptor agonist treatment with rM3Ds-dSPN stimulation reproduced all sym

228 Subsequent treatment with RNase H releases RNA-templated ligation p

229 Treatment with Ro 61-8048 decreased nicotine self-admini

230 this study, we assessed the effect of 2-year treatment with rosuvastatin on carotid IMT in children w

231 Treatment with sapropterin, a tetrahydrobiopterin analog

232 oximately 30% in cystic cholangiocytes after treatment with SBI-115 alone and by approximately 50% wh

233 Forty patients were randomized 1:1 to treatment with serelaxin intravenous (i.v.) infusion (fo

234 Treatment with serelaxin prevented cardiac and renal dys

235 Treatment with sitagliptin plus basal insulin is as effe

236 We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pange

237 stained virologic response after 12 weeks of treatment with sofosbuvir and velpatasvir.

238 ificant predictors of improved survival were treatment with sorafenib (hazard ratio [HR], 0.66; 95% c

239 Treatment with specific GSK3 inhibitor (L803-mts), start

240 tudy was to examine the associations between treatment with statins, renin-angiotensin system blocker

241 Three years of continuous treatment with subcutaneous immunotherapy and sublingual

242 fants with the neonatal abstinence syndrome, treatment with sublingual buprenorphine resulted in a sh

243 (SC) expressing ENb-TRAIL, we show that the treatment with synthetic extracellular matrix (sECM) enc

244 s the rate of asthma exacerbations requiring treatment with systemic corticosteroids.

245 osphoproteome in the Jurkat T cell line upon treatment with T cell stimulating agents.

246 rm that both exemestane alone and sequential treatment with tamoxifen followed by exemestane are reas

247 dine and a platinum agent, followed by later treatment with taxanes and irinotecan, provides some ben

248 Finally, treatment with TC14012 also significantly increased PI3K

249 terone and age-associated memory impairment, treatment with testosterone for 1 year compared with pla

250 formed to combine direct comparisons between treatments with that of indirect simulated evidence.

251 levels of overexpressed FLIL33, reversed by treatment with the 20S proteasome inhibitor bortezomib.

252 Moreover, treatment with the alphaAnalogue was well tolerated with

253 Treatment with the anti-ERBB2 humanized monoclonal antib

254 In mice with MAS, treatment with the anti-IFN-gamma antibody significantly

255 Treatment with the ATR-selective inhibitor AZ20 caused p

256 as it is rapidly phosphorylated in vivo upon treatment with the bacterial MAMP flg22.

257 l lines with acquired resistance to combined treatment with the BRAF inhibitor vemurafenib and the mi

258 pVHL), a negative regulator of HIF, and that treatment with the c-src inhibitor PP2 rescued this effe

259 ctivation of leukocytes with LPS followed by treatment with the calcium ionophore A23187 resulted in

260 n multiple cohorts of AML patients receiving treatment with the cytidine nucleoside analogue cytarabi

261 Treatment with the epithelial Na(+) channel blocker amil

262 he hydrogel, as well as cell viability after treatment with the hydrogel containing naringin, were ev

263 Finally, daily treatment with the hypotonic 2-PMPA enema ameliorated ma

264 titutive activation was abrogated by ex vivo treatment with the janus kinase 1/2 inhibitor ruxolitini

265 Treatment with the Janus kinase 1/2 inhibitor ruxolitini

266 helix peptide, the present study showed that treatment with the Kalpha2 peptide fused with the TAT pe

267 We have shown that treatment with the KATP channel agonist pinacidil increa

268 cation following infection with FHV, whereas treatment with the KATP channel antagonist tolbutamide d

269 In addition, treatment with the mitochondrial Ca(2+)-buffering protei

270 Treatment with the monoclonal antibody E06 or with apoli

271 These results were mimicked by treatment with the myosin II inhibitor blebbistatin.

272 timulated gene (ISG) transcription following treatment with the noncanonical cyclic dinucleotide 2',3

273 Low dosage treatment with the pBtk inhibitor Ibrutinib reversed the

274 We found that treatment with the physiological NO donor S-nitrosogluta

275 WT vs. CD-WT mice, which was prevented by co-treatment with the reactive oxygen species scavenger Tem

276 INTERPRETATION: Re-treatment with the same ACT shows similar efficacy as re

277 r epithelial cells in vitro and in vivo, and treatment with the small molecule TNFR inhibitor R-7050

278 Treatment with the small-molecule CD11b agonist LA1 led

279 We compared this treatment with the standard of care, active surveillance

280 efficiently inhibited tumor growth following treatment with the therapeutic antibody rituximab.

281 d EG7-OVA tumor growth in mice, however only treatment with the thioether linked vaccine construct re

282 mplementary in vivo studies demonstrate that treatment with the TLR7 ligand imiquimod can inhibit Th1

283 On treatment with the toll-like receptor 7 agonist imquimod

284 Systemic and ocular treatment with the TR antagonists NH-3 and 1-850 increas

285 ring the intracellular zinc concentration by treatment with the zinc chelator N,N,N'-tetrakis-(2'-pyr

286 psychotic medications were the pharmacologic treatments with the highest rates of prevention of relap

287 Treatment with this enzyme selectively causes cell cycle

288 Treatment with tocilizumab in 13 subjects resulted in ra

289 gely maintained after 16 weeks of successful treatment with topical triamcinolone.

290 Furthermore, treatment with tPA led to decompression of blood vessels

291 Macular oedema responded to intravitreal treatment with triamcinolone.

292 Our results showed that upon treatment with triptolide, HIF-1alpha protein accumulate

293 Combination treatment with TSLDox and HT in vivo was significantly m

294 eases in VCAM-1 and leukocyte adhesion after treatment with tumour necrosis factor-alpha.

295 imes the upper limit of normal (ULN) despite treatment with ursodeoxycholic acid.

296 In a proof-of-concept setting systemic treatment with ustekinumab diminished imiquimod-induced

297 We also found that treatment with VEGFA reduced expression of CX3CL1 in end

298 icant differences of the NOACs compared with treatment with warfarin across strata were evident.

299 re Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn an

300 s and fracture resistance when compared with treatment with zoledronic acid alone.